Val-083 Clinical Trials

About Kintara Therapeutics

About Kintara Therapeutics

Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer.

We have acquired certain exclusive commercial rights in China where VAL-083 is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer.

Learn More about Kintara Therapeutics

About the Clinical Trials

VAL-083 is a structurally unique, "first-in- class", small-molecule chemotherapeutic. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).

Brain Tumor Trials

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Recruiting

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE): More Information

Brain Tumor Trials

Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting

Active, not recruiting

The purpose of this phase 2, two arm, biomarker-driven study is to determine if treatment of

For Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma: More Information

Brain Tumor Trials

Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression

Active, not recruiting

The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the

For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More Information

Solid Tumor Trials

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer

Withdrawn

This is an open label, multi-center, Phase 1/2 clinical trial in subjects with recurrent

A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer (REPROVe): More Information

Brain Tumor Trials

Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma

Completed

The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and

For Patients With Recurrent Malignant Glioma: More Information